University of Maryland
RNA Disease Diagnostics to Develop Point-of-Care Coronavirus Test With Newly Licensed Tech
The company said it intends to use the technology to develop infectious disease diagnostics, with an initial focus on SARS-CoV-2.
In Fight Against Coronavirus, Developers Turn to Emerging, As Well As Established, Technologies
Emerging technologies included biosensors, host response tests using different types of biomarkers, and new ways to make and develop antigen, antibody, and PCR tests.
Called the "Ccheck Prostate Cancer Confirmation" test, Anixa's assay integrates flow cytometry and machine learning to identify evidence of cancer in a person's bloodstream.
The firm aims to have its test on the European clinical market by early next year, followed by a launch in the US.
Researchers implemented qPCR on TaqMan Array Cards to find six pathogens are responsible for up to 90 percent of childhood diarrhea at seven sites in Africa and Asia.